This article is more than 5 years old. Information may no longer be current.
Subconjunctival anti-VEGF injection reduces corneal neovascularization
Click Here to Manage Email Alerts
PARIS — Subconjunctival injection of bevacizumab seems to be effective in reducing corneal neovascularization, according to a study carried out in Rouen, France.
"A single dose of 0.1 mL bevacizumab (25 mg/mL) was injected under the conjunctiva, as near as possible to the site of neovascularization, under local anesthesia, in 13 eyes of 12 patients. The patients received between two and four injections over a period of 4 months," Julie Gueudry, MD, said at the meeting of the French Society of Ophthalmology.
However, visual acuity did not significantly improve, and three cases of corneal epithelial ulcers were reported.
"Corneal ulceration is an adverse effect that we must consider," Dr. Gueudry said.
No alteration of IOP and no systemic side effects were observed.
Less invasive and more comfortable means of administering anti-VEGF agents to the eye, such as topical eye drops, are currently under investigation and might be an alternative in the future.